ArticleGastroenterology research and practice2012
How many diseases are colorectal cancer?
Article in Gastroenterology research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 27 citations in OpenAlex.
- Biphasic Expression of Atypical Chemokine Receptor (ACKR) 2 and ACKR4 in Colorectal Neoplasms in Association with Histopathological Findings.Biomolecules · 2020Article
- Local and Systemic Interleukin-32 in Esophageal, Gastric, and Colorectal Cancers: Clinical and Diagnostic Significance.Diagnostics (Basel, Switzerland) · 2020Article
- The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study.The Korean journal of internal medicine · 2019Article
- Left-sided primary tumor is a favorable prognostic factor for metastatic colorectal cancer patients receiving surgery.Oncotarget · 2017Article
- Segmental distribution of some common molecular markers for colorectal cancer (CRC): influencing factors and potential implications.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Male pattern baldness and risk of colorectal neoplasia.British journal of cancer · 2016Article
- Review
- The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.Therapeutic advances in gastroenterology · 2013Article
- Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2013Review
- Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status.Cancer research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differences in the aetiology and epidemiology of proximal and distal cancers are reflected in different clinical behaviour, histopathology, and molecular characteristics of these tumours. This may impact response both to standard cytotoxic therapies and mechanism-targeted agents. This disease heterogeneity leads to challenges in the design of clinical trials to assess novel therapies in the treatment of "colorectal cancer."
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.